Peter Svennilson

Managing Partner and Founder

2007 - Current

Peter Svennilson founded The Column Group in 2007 and has worked in venture capital and finance for over 30 years. He was the Chairman of Aragon Pharmaceuticals from startup until it was sold to Johnson & Johnson in 2013 and was the Chairman of Seragon Pharmaceuticals until it was sold to Genentech/ Roche in 2014. He is the Chairman of ORIC Pharmaceuticals and a Board Director of Gritstone, NGM Biopharmaceuticals, Immune Design, and Constellation Pharmaceuticals. Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies such as Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, Somalogic, Infinity and Fiveprime. Prior to Three Crowns Capital he was the Associate Managing Director in charge of European Investment Banking Origination at Nomura in London. Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton. Board of Directors: ORIC Pharmaceuticals (Chairman), Gritstone Oncology, Immune Design, NGM Biopharmaceuticals, Constellation Pharmaceuticals

Managing Partner and Founder

1996 - 2006